🟢 Novo Nordisk is trading 3.31% up today after JPMorgan raised 2026 sales expectations

Novo Nordisk is trading at €41.35 (+3.31%) after JPMorgan raised its 2026 sales expectations and price target from DKK 250 to DKK 275.

• JPMorgan cited limited generic pressure, favorable U.S. adjustments, and stronger-than-expected Wegovy growth outside the United States.
• The move appears company-specific rather than broad-market driven; major U.S. indices were up less than 0.5% on August 25, 2026.